MX2022003065A - Conjugados de proteína-macromolécula y métodos de uso de estos. - Google Patents
Conjugados de proteína-macromolécula y métodos de uso de estos.Info
- Publication number
- MX2022003065A MX2022003065A MX2022003065A MX2022003065A MX2022003065A MX 2022003065 A MX2022003065 A MX 2022003065A MX 2022003065 A MX2022003065 A MX 2022003065A MX 2022003065 A MX2022003065 A MX 2022003065A MX 2022003065 A MX2022003065 A MX 2022003065A
- Authority
- MX
- Mexico
- Prior art keywords
- conjugates
- protein
- methods
- macromolecule
- macromolecule conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción proporciona conjugados de proteína-macromolécula, enlazadores liberables y macromoléculas, tal como se define en la presente. Los conjugados descritos proporcionan propiedades únicas que se basan al menos en las propiedades del enlazador y la cantidad de restos enlazador-macromolécula. También se proporciona en la presente un método de síntesis y uso de conjugados en el tratamiento de enfermedades y trastornos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962908435P | 2019-09-30 | 2019-09-30 | |
PCT/US2020/053572 WO2021067458A1 (en) | 2019-09-30 | 2020-09-30 | Protein-macromolecule conjugates and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022003065A true MX2022003065A (es) | 2022-06-09 |
Family
ID=75337536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022003065A MX2022003065A (es) | 2019-09-30 | 2020-09-30 | Conjugados de proteína-macromolécula y métodos de uso de estos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220401561A1 (es) |
EP (1) | EP4037715A4 (es) |
JP (1) | JP2022549295A (es) |
KR (1) | KR20220074897A (es) |
CN (1) | CN114630818A (es) |
AU (1) | AU2020360397A1 (es) |
BR (1) | BR112022005465A2 (es) |
CA (1) | CA3153644A1 (es) |
IL (1) | IL291730A (es) |
MX (1) | MX2022003065A (es) |
TW (1) | TW202126332A (es) |
WO (1) | WO2021067458A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022103983A2 (en) * | 2020-11-11 | 2022-05-19 | Sutro Biopharma, Inc. | Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use |
CN113929731B (zh) * | 2021-12-16 | 2022-05-10 | 北京春雷杰创生物科技有限公司 | 一种促进低分子量蛋白体外复性和提高免疫原性的方法 |
WO2023244517A1 (en) * | 2022-06-16 | 2023-12-21 | Merck Sharp & Dohme Llc | Interleukin-2 prodrugs |
CN115947745B (zh) * | 2022-12-26 | 2024-02-27 | 中山大学 | 一种基于白蛋白的光热转换纳米材料及其制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100240773A1 (en) * | 2009-03-23 | 2010-09-23 | Kenneth Korzekwa | Multifunctional linkers |
WO2011140376A1 (en) * | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from dendrimers |
ES2584381T3 (es) * | 2010-05-05 | 2016-09-27 | Prolynx Llc | Liberación controlada de compuestos activos desde conjugados macromoleculares |
EP2566334B1 (en) * | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
KR102109067B1 (ko) * | 2011-09-07 | 2020-05-13 | 프로린크스 엘엘시 | 생분해성 교차결합을 가지는 하이드로젤 |
WO2013036857A1 (en) * | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
EP2768856A4 (en) * | 2011-10-18 | 2015-05-27 | Prolynx Llc | PEG CONJUGATES OF EXENATIDE |
KR20160075665A (ko) * | 2013-10-22 | 2016-06-29 | 프로린크스 엘엘시 | 소마토스타틴 및 그 유사체의 컨쥬게이트 |
EP3598983A1 (en) * | 2014-10-03 | 2020-01-29 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
-
2020
- 2020-09-30 US US17/764,475 patent/US20220401561A1/en active Pending
- 2020-09-30 MX MX2022003065A patent/MX2022003065A/es unknown
- 2020-09-30 CA CA3153644A patent/CA3153644A1/en active Pending
- 2020-09-30 BR BR112022005465A patent/BR112022005465A2/pt unknown
- 2020-09-30 TW TW109134302A patent/TW202126332A/zh unknown
- 2020-09-30 JP JP2022518653A patent/JP2022549295A/ja active Pending
- 2020-09-30 WO PCT/US2020/053572 patent/WO2021067458A1/en unknown
- 2020-09-30 KR KR1020227012420A patent/KR20220074897A/ko unknown
- 2020-09-30 CN CN202080068415.6A patent/CN114630818A/zh active Pending
- 2020-09-30 EP EP20871115.0A patent/EP4037715A4/en active Pending
- 2020-09-30 AU AU2020360397A patent/AU2020360397A1/en active Pending
-
2022
- 2022-03-27 IL IL291730A patent/IL291730A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP4037715A4 (en) | 2023-12-13 |
BR112022005465A2 (pt) | 2022-06-14 |
AU2020360397A1 (en) | 2022-03-31 |
TW202126332A (zh) | 2021-07-16 |
CA3153644A1 (en) | 2021-04-08 |
US20220401561A1 (en) | 2022-12-22 |
KR20220074897A (ko) | 2022-06-03 |
JP2022549295A (ja) | 2022-11-24 |
IL291730A (en) | 2022-05-01 |
CN114630818A (zh) | 2022-06-14 |
WO2021067458A1 (en) | 2021-04-08 |
EP4037715A1 (en) | 2022-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022003065A (es) | Conjugados de proteína-macromolécula y métodos de uso de estos. | |
AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
MX2020002666A (es) | Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato. | |
NZ754051A (en) | Novel antibodies and uses thereof | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
PH12018501777A1 (en) | Derivatives of amanita toxins and their conjugation to a cell binding molecule | |
NZ725480A (en) | Anti-ptk7 antibody-drug conjugates | |
WO2018236870A3 (en) | METHODS AND COMPOSITIONS FOR TARGETING CANCER CELLS WITH A CHIMERIC ANTIGENIC RECEPTOR | |
NZ741261A (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
WO2015151080A3 (en) | Specific conjugation of cell-binding molecules | |
MX2020012997A (es) | Conjugados de anticuerpo modulador de empalme-farmaco y metodos de uso. | |
MX2021010550A (es) | Conjugados de anticuerpo-farmaco hidrofilicos. | |
NZ737471A (en) | Hydrophilic linkers for conjugation | |
MY148860A (en) | Fused amino pyridine as hsp90 inhibitors | |
MX2010000465A (es) | Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores. | |
MX2010005022A (es) | Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas. | |
MX2015011583A (es) | Derivados de amatoxina. | |
JOP20210253A1 (ar) | أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ psma | |
JOP20210323A1 (ar) | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 | |
MX2021015533A (es) | Anticuerpos anti-mesotelina e inmunoconjugados de los mismos. | |
JOP20190191A1 (ar) | وحدات شجرية علاجية | |
ZA202203201B (en) | Therapeutic conjugates | |
GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
MX2021003186A (es) | Nuevos conjugados de hidrogel. | |
MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. |